---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-003047"
form_type: "8-K"
ticker: "CATX"
cik: "0000728387"
company_name: "Perspective Therapeutics, Inc."
filed_at: "2023-02-10T23:59:59+00:00"
generated_at: "2026-06-19T18:38:37.127218+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Isoray terminates Chief R&D Officer William Cavanagh III, expects separation agreement

## Summary
- William Cavanagh III terminated as Chief R&D Officer effective Feb 7, 2023; termination triggers his Employment Agreement change-of-control provisions.
- Expected separation agreement: accrued wages at $341K annual salary, unreimbursed expenses (request within 5 days), plus one year health insurance premiums.
- Separation agreement will include a release of all claims by Cavanagh against the company; no assurance it will be finalized.
- Cavanagh remains subject to non-solicitation, non-disparagement, and confidentiality obligations post-termination.

## SEC filing metadata
- accession: 0001437749-23-003047
- form_type: 8-K
- ticker: CATX
- cik: 0000728387
- company_name: Perspective Therapeutics, Inc.
- filed_at: 2023-02-10T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.02, 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/728387/000143774923003047/0001437749-23-003047-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/728387/000143774923003047/isr20230210_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-003047
- JSON: https://secwatch.observer/filing/0001437749-23-003047.json
- Plain text: https://secwatch.observer/filing/0001437749-23-003047.txt

## Key facts
- Executive change
  William Cavanagh III was terminated as Chief Research and Development Officer at Perspective Therapeutics, Inc..
  - Action: terminated
  - Role: Chief Research and Development Officer
  source text: William Cavanagh III was terminated from his position of Chief Research and Development Officer of the Company on February 7, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/728387/000143774923003047/0001437749-23-003047-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.